Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma. Issue 9 (March 2018)
- Record Type:
- Journal Article
- Title:
- Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma. Issue 9 (March 2018)
- Main Title:
- Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma
- Authors:
- Zhang, Ping
Nie, Xin
Bie, Zhixin
Li, Lin - Other Names:
- Efird. Jimmy T. section editor.
- Abstract:
- Abstract : Abstract: Smoking is a risk factor for nonsmall cell lung carcinoma (NSCLC) and is associated with a lower response to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI). The purpose of this study is to examine the impact of the smoking status on the benefits from first-line EGFR-TKI in NSCLC patients with EGFR mutation. This was a retrospective study of 159 patients with advanced NSCLC treated at the Beijing Hospital between January 2011 and December 2016. The follow-up was censored on December 2017. EGFR mutation status, smoking (nonsmoker vs <30 packs/year (light smoker) vs ≥30 packs/year (heavy smoker)), treatment, treatment response, and progression-free survival (PFS) were collected from the charts. Median follow-up was 10.0 (1.0–36.6) months. Response rate was lower in heavy smokers compared with nonheavy smokers (19.0% vs 71.7%, P < .001). There was no difference in PFS between nonsmokers (median, 10.5 months) and light smoker (median, 11.0 months), and these 2 groups were pooled together. PFS was longer in nonheavy smokers compared with heavy-smokers (median, 10.7 vs 6.0 months, P < .001). Smoking ≥ 30 packs/year (HR = 2.48, 95% CI: 1.55–3.98, P < .001) was associated with PFS. In patients with advanced NSCLC, the benefits and PFS of EGFR-TKI were better for nonheavy smokers than for heavy smokers.
- Is Part Of:
- Medicine. Volume 97:Issue 9(2018)
- Journal:
- Medicine
- Issue:
- Volume 97:Issue 9(2018)
- Issue Display:
- Volume 97, Issue 9 (2018)
- Year:
- 2018
- Volume:
- 97
- Issue:
- 9
- Issue Sort Value:
- 2018-0097-0009-0000
- Page Start:
- Page End:
- Publication Date:
- 2018-03
- Subjects:
- chemotherapy -- epidermal growth factor receptor-tyrosine kinase inhibitors -- nonsmall cell lung carcinoma -- smoking -- survival
Medicine -- Periodicals
Medicine -- Periodicals
Médecine -- Périodiques
Geneeskunde
Medicine
Periodicals
Periodicals
610.5 - Journal URLs:
- http://journals.lww.com/md-journal/pages/default.aspx ↗
http://gateway.ovid.com/ovidweb.cgi?T=JS&PAGE=toc&D=ovft&MODE=ovid&NEWS=N&AN=00002060-000000000-00000 ↗
http://journals.lww.com ↗ - DOI:
- 10.1097/MD.0000000000010006 ↗
- Languages:
- English
- ISSNs:
- 0025-7974
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5534.000000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 6341.xml